株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

膣萎縮 (萎縮性腟炎) :パイプライン製品の分析

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 326371
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
膣萎縮 (萎縮性腟炎) :パイプライン製品の分析 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 52 Pages
概要

膣萎縮は萎縮性腟炎とも呼ばれ、エストロゲンの減少から膣壁が薄くなり、乾燥し、炎症を起こした状態をいいます。乾燥、膣分泌物、掻痒、排尿時灼熱感、尿意切迫、尿路感染症、尿失禁などの兆候および症状があります。喫煙などが素因であり、局所用 (膣用) エストロゲン剤、全身用エストロゲン剤の利用などの治療法があります。

当レポートでは、世界における膣萎縮 (萎縮性腟炎) のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要 (製品概要、機能メカニズム、研究開発の進展状況) 、最新の業界動向などを調査した結果をお届けします。

イントロダクション

  • 調査範囲

膣萎縮 (萎縮性腟炎) の概要

治療薬の開発

  • パイプライン製品の概要

膣萎縮 (萎縮性腟炎):企業で開発中の治療薬

膣萎縮 (萎縮性腟炎):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

膣萎縮 (萎縮性腟炎):企業で開発中の製品

膣萎縮 (萎縮性腟炎) の治療薬開発に従事している企業

  • EndoCeutics, Inc.
  • Foamix Pharmaceuticals Ltd.
  • Ligand Pharmaceuticals, Inc.
  • Mithra Pharmaceuticals S.A.
  • PEPTONIC medical AB
  • TherapeuticsMD, Inc.

膣萎縮 (萎縮性腟炎):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

膣萎縮 (萎縮性腟炎):最近のパイプライン動向

膣萎縮 (萎縮性腟炎):休止中のプロジェクト

膣萎縮 (萎縮性腟炎):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8683IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2016, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 1 respectively.Vaginal Atrophy (Atrophic Vaginitis).

Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vaginal Atrophy (Atrophic Vaginitis) Overview
  • Therapeutics Development
    • Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview
  • Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies
  • Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development
    • Allergan Plc
    • EndoCeutics, Inc.
    • Foamix Pharmaceuticals Ltd.
    • Ligand Pharmaceuticals, Inc.
    • Mithra Pharmaceuticals S.A.
    • PEPTONIC medical AB
  • Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Estetrol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • estradiol hemihydrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lasofoxifene tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxytocin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prasterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WC-3011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects
  • Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones
    • Featured News & Press Releases
      • May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
      • Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study
      • Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting
      • Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause
      • Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting
      • Jul 17, 2015: Last subject exits Peptonic Medical's phase 2b VVA study
      • Mar 30, 2015: Vulvovaginal atrophy symptoms improve with prasterone treatment
      • Mar 23, 2015: Peptonic Medical's formulation patent to be approved in the USA
      • Mar 18, 2015: Patient recruitment to Peptonic Medical's phase 2b study soon completed
      • Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin
      • Dec 01, 2014: Peptonic Medical's formulation patent to be approved in Europe
      • Oct 28, 2014: First patients included in Peptonic Medical AB's clinical phase 2b study
      • Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study
      • Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study
      • Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Allergan Plc, H2 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H2 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals S.A., H2 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by PEPTONIC medical AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top